drugset / Trial / NCT01099215

Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)

NCT01099215 ↗

Phase 1/2 Completed 21 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic cellular therapy, delivered as a single injection following percutaneous transluminal ("balloon") angioplasty and stent placement for the treatment of peripheral artery disease (PAD).

Timeline

Start
2010-04-30
Primary completion
2012-06-30
Completion
2012-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PVS-10200 Cell therapy — Other